Citation: | LIU Xiyang, AN Yingying, YU Baoguo, et al., “Analysis of Commonly and Specifically Dysregulated Pathways in Three Women Cancers,” Chinese Journal of Electronics, vol. 27, no. 5, pp. 1043-1049, 2018, doi: 10.1049/cje.2017.09.028 |
M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, et al., “Prospective identification of tumorigenic breast cancer cells”, Proc. Natl. Acad. Sci. USA, Vol.100, No.7, pp.3983-3988, 2003.
|
The Cancer Genome Atlas Research Network, “Integrated genomic characterization of endometrial carcinoma”, Nature, Vol.497, No.7447, pp.67-73, 2013.
|
The Cancer Genome Atlas Research Network, “Integrated genomic analysis of ovarian carcinoma”, Nature, Vol.474, No.27, pp.609-615, 2011.
|
M.C. Pike, “Age-related factors in cancers of the breast, ovary, andendometrium”, J. Chronic Dis., Vol.40, No.87, pp.59S-69S, 1987.
|
J.F. Ludvigsson, J. West, A. Ekbom, et al., “Reduced risk of breast, endometrial and ovarian cancer in women with celiac disease”, Int. J. Cancer, Vol.131, No.3, pp.E244-250, 2012.
|
M. Grechkin, B.A. Logsdon, A.J. Gentles, et al., “Identifying network perturbation in cancer”, PLOS Comput. Biol., Vol.12, No.5, 2016.
|
H. Yang, Q. Wei, X. Zhong, et al., “Cancer driver gene discovery through an integrative genomics approach in a non-parametric Bayesian framework”, Bioinformatics, Vol.33, No.4, pp.483-490, 2016.
|
H.Y. Chuang, E. Lee, Y.T. Liu, et al., “Network-based classification of breast cancer metastasis”, Mol. Syst. Biol., Vol.3, No.1, pp.1440-1449, 2007.
|
T.H. Hwang, G. Atluri, R. Kuang, et al., “Large-scale integrative network-based analysis identifies common pathways disrupted by copy number alterations across cancers”, BMC Genomics, Vol.14, No.1, pp.440-452, 2013.
|
F. Vandin, E. Upfal and B.J. Raphael, “Algorithms for detecting significantly mutated pathways in cancer”, J. Comput. Biol., Vol.18, No.3, pp.507-522, 2011.
|
W. Poole, K. Leinonen, I. Shmulevich, et al., “Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression”, PLOS Comput. Biol., Vol.13, No.2, DOI: 10.1371/journal.pcbi.1005347, 2017.
|
D. Tanramluk, L. Narupiyakul, R. Akavipat, et al., “MANORAA (Mapping analogous nuclei onto residue and affinity) for identifying protein-ligand fragment interaction, pathways and SNPs”, Nucleic Acids Res., Vol.44, No.W1, pp.W514-W521, 2016.
|
The Cancer Genome Atlas Research Network, “The cancer genome atlas pan—Cancer analysis project”, Nat. Genet., Vol.45, No.10, pp.1113-1120, 2013.
|
K.A. Hoadley, C. Yau, D.M. Wolf, et al., “Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin”, Cell, Vol.158, No.4, pp.929-944, 2014.
|
A. Liberzon, A. Subramanian, R. Pinchback, et al., “Molecular signatures database (MSigDB) 3.0”, Bioinformatics, Vol.27, No.12, pp.1739-1740, 2011.
|
S. Peri, J.D. Navarro, R.Amanchy, et al., “Development of human protein reference database as an initial platform for approaching systems biology in humans”, Genome Res., Vol.13, No.10, pp.2363-2371, 2003.
|
K.G. Becker, K.C. Barnes, T.J. Bright, et al., “The genetic association databas”, Nat. Genet., Vol.36, No.5, pp.431-432, 2004.
|
P.A. Futreal, L. Coin, M. Marshall, et al., “A census of human cancer genes”, Nat. Rev. Cancer, Vol.4, No.3, pp.177-183, 2004.
|
A. Hamosh, A.F. Scott, J.S. Amberger, et al., “Online mendelian inheritance in man (OMIM), a knowledgebase of human genes and genetic disorders”, Nucleic Acids Res., Vol.33, No.1, pp.D514-517, 2005.
|
R.A. Fisher, “Statistical methods for research workers”, Int. J. Plant Sciences, Vol.96, No.3, pp.340-341, 1935.
|
J.A. Royds, S.K. Dower, E.E. Qwarnstrom, et al., “Response of tumour cells to hypoxia: Role of p53 and NFkB”, Mol. Pathol., Vol.51, No.2, pp.55-61, 1998.
|
A.L. Harris, “Hypoxia — a key regulatory factor in tumour growth”, Nat. Rev. Cancer, Vol.2, No.1, pp.38-47, 2002.
|
C. Lagadec, S. Meignan and E. Adriaenssens, “TrkA overexpression enhances growth and metastasis of breast cancer cells”, Oncogene, Vol.28, No.18, pp.1960-1970, 2009.
|
S.M. Albelda, “Role of integrins and other cell adhesion molecules in tumor progression and metastasis”, Lab Invest, Vol.68, No.1, pp.4-17, 1993.
|
S.L. Bowker, S.R. Majumdar, P. Veugelers, et al., “Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin”, Diabetes Care, Vol.29, No.29, pp.254-258, 2006.
|
M.R. Junttila and F.J. Sauvage, “Influence of tumourmicroenvironment heterogeneity on therapeutic response”, Nature, Vol.501, No.7467, pp.346-54, 2013.
|
D.G. DeNardo, D.J. Brennan, E. Rexhepaj, et al., “Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy”, Cancer Discov., Vol.1, No.1, pp.54-67, 2011.
|
D.G. DeNardo and L.M. Coussens, “Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression”, Breast Cancer Res., Vol.9, No.4, pp.212-221, 2007.
|
N.S. Brown and R. Bicknell, “Hypoxia and oxidative stress in breast cancer. Oxidative stress: Its effects on the growth, metastatic potential and response to therapy of breast cancer”, Breast Cancer Res., Vol.3, No.5, pp.323-327, 2001.
|
D. Hanahan and R.A. Weinberg, “The hallmarks of cancer”, Cell, Vol.100, No.1, pp.57-70, 2000.
|
V. Zuco, V. Benedetti, M. De Cesare, et al., “Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: Enhanced DNA damage response”, Int. J. Cancer, Vol.126, No.5, pp.1246-1255, 2010.
|
J. Kang, A.D. D’Andrea and D. Kozono, “A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy”, J. Natl. Cancer Inst., Vol.104, No.9, pp.670-681, 2012.
|
A.S. Swierzko, K. Florczak, M. Cedzyński, et al., “Mannanbinding lectin (MBL) in women with tumours of the reproductive system”, Cancer Immunology Immunotherapy, Vol.56, No.7, pp.959-71, 2007.
|
H. Pendeville, N. Carpino and J.C. Marine, “The ornithine decarboxylase gene is essential for cell survival during early murine development”, Mol Cell Biol., Vol.21, No.19. pp.6549-58, 2001.
|
C.F. Holinka and E. Gurpide, “Ornithine decarboxylase activity in human endometrium and endometrial cancer cells”, In Vitro Cell. & Dev. Biology-Animal, Vol.21, No.12, pp.697-706, 1985.
|
J. Adams, V.J. Palombella, E.A. Sausville, et al., “Proteasome inhibitors: A novel class of potent and effective antitumor agents”, Cancer Res., Vol.59, No.11, pp.2615-2622, 1999.
|
E.E. Bosco, Y. Wang, H. Xu, et al., “The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer”, J. Clin. Invest., Vol.117, No.1, pp.218-228, 2007.
|
Y. Dong, M.D. Walsh, M.A. McGuckin, et al., “Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer”, Int. J. Cancer, Vol.74, No.4, pp.407-415, 1997.
|
R.J. DeBerardinis, J.J. Lum, G. Hatzivassiliou, et al., “The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation”, Cell Metab., Vol.7, No.1, pp.11-20, 2008.
|
D.W. Cramer, “Lactase persistence and milk consumption as determinants of ovarian cancer risk”, Am. J. Epidemiol., Vol.130, No.5, pp.904-910, 1989.
|
W.Y. Chen, E.R. Bertone-Johnson, D.J. Hunter, et al., “Associations between polymorphisms in the vitamin D receptor and breast cancer risk”, Cancer Epidemiol. Biomarkers & Prev., Vol.14, No.10, pp.2335-2339, 2005.
|
H. Yabushita, M. Hirata, M. Noguchi, et al., “Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines”, J. Obstet. and Gynaecol. Res., Vol.22, No.6, pp.529-539, 1996.
|
Y. Zhang, Y. Xiong and W.G. Yarbrough, “ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways”, Cell, Vol.92, No.6, pp.725-734, 1998.
|
K. Ino, K. Shibata, H. Kajiyama, et al., “Angiotensin Ⅱ type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival”, Br. J. Cancer, Vol.94, No.4, pp.552-560, 2006.
|
A.W. Piastowska-Ciesielska, E. P luciennik, K. WójcikKrowiranda, et al., “Analysis of the expression of angiotensin Ⅱ type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics”, Tumour Biol., Vol.33, No.3, pp.767-774, 2012.
|
G.F. Nash, D.C. Walsh and A.K. Kakkar, “The role of the coagulation system in tumour angiogenesis”, Lancet Oncol., Vol.2, No.10, pp.608-613, 2001.
|
M. Cizkova, S. Vacher, D. Meseure, et al., “PIK3R1 underexpression is an independent prognostic marker in breast cancer”, BMC Cancer, Vol.13, N0.1, Page 545, 2013.
|
B. Woynarowska, D.M. Skrincosky, A. Haag, et al., “Inhibition of lectin-mediated ovarian tumor cell adhesion by sugar analogs”, J. Biol. Chem., Vol.269, No.36, pp.22797-803, 1994
|
P. Mehlen, S. Rabizadeh S.J. Snipas, et al., “The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis”, Nature, Vol.395, pp.801-804, 1998
|
H. Kato, Y. Zhou, K. Asanoma, et al., “Suppressed tumorigenicity of human endometrial cancer cells by the restored expression of the DCC gene”, Br. J. Cancer, Vol.82, No.2, pp.459-466, 2000.
|